74 results about "Truncal muscle weakness" patented technology

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (such as anemia).

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and / or cardiometabolic disease, bone damage, and / or low red blood cell levels (such as anemia).

The invention discloses a method and a system for identifying muscular weakness of a critical patient, and relates to the field of muscular weakness identification. Subjective clinical muscular strength grading of the patient and instrument detection data are integrated, a muscular weakness grade mapping model of multiple parts is established, and the diagnosis accuracy is greatly improved; through a host / guest part mapping model, namely in combination with subjective feeling and objective detection data of a patient, the medullary muscular weakness symptom prone to missed diagnosis in traditional examination can be identified; on the basis of a muscle weakness index data prediction mechanism, a muscle weakness crisis risk can be warned in advance; through a treatment-evaluation-adjustment closed-loop system, dynamic optimization of a medicine scheme is realized, the crisis occurrence rate can be greatly reduced, the dosage of an immunosuppressive agent is reduced, meanwhile, the treatment effect is maintained, and the system is suitable for patient groups managed for a long time; by establishing a mapping system of a part type set and an index grade set, quantitative unified evaluation of different types such as eye muscle type / whole body type and the like is realized, and subjective judgment errors are reduced.

The present invention provides compositions and methods of their use in treating dystroglycanopathy, muscular dystrophy and other disorders. In particular, a method of treating a disorder associated with a mutation or loss of function in a fukutin related protein (FKRP) gene and / or a disorder associated with a defect in glycosylation of α-DG in a subject is provided, comprising administering to the subject an effective amount of a ribitol and a selective estrogen receptor modulator (SERM).

The present invention relates to a composition, for preventing, relieving, or treating a muscle weakness-related disease, comprising a celery seed extract. The celery seed extract according to the present invention causes a few or no side effects by using a natural product, may increase muscle mass and muscle strength to not only prevent muscle weakness but also inhibit weight gain and body fat increase, and may reduce serum lipid profiles and hepatotoxicity markers (GOT and GPT), and thus is expected to be utilized for preventing, relieving, or treating muscle weakness-related diseases, metabolic diseases, liver diseases, or the like.

Disclosed herein is related to a method for extending lifespan and / or delaying aging in a subject; the method comprises administering to the subject with an effective amount of (24S)-3β-hydroxy-5α-stigmastan-6-one, wherein the delaying aging comprises increasing vitality, muscle strength or motor coordination, insulin sensitivity, or basal metabolic rate; and / or reducing muscle weakness, loss of balance, hair graying, kyphosis, or hyperglycemia. Also encompassed in the present disclosure are methods for promoting weight loss or treating type 2 diabetes mellitus in a subject, in which the methods comprise administering to the subject an effective amount of (24S)-3β-hydroxy-5α-stigmastan-6-one.

The present invention relates to activin receptor IIA type variants and methods of use thereof. The present invention features a polypeptide comprising an extracellular ActRIIa variant. In some embodiments, the polypeptides of the present invention comprise an extracellular ActRIIa variant fused to an Fc domain monomer or part. The invention also features the treatment of diseases and conditions involving muscle weakness and atrophy using said polypeptides, such as Duchenne muscular dystrophy, facial shoulder brachial muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; the present invention relates to pharmaceutical compositions and methods for treating a metabolic disease, such as obesity, type 1 diabetes mellitus or type 2 diabetes mellitus.

The application discloses a gene editing system for constructing a muscle weakness disease model pig nuclear transfer donor cell with a DOK7 gene mutation and application thereof. The application provides application of DOK7-gRNA2 shown in SEQ ID NO: 16, DOK7-gRNA4 shown in SEQ ID NO: 17 and NCN protein in preparation of a kit. The application further provides a method for preparing a recombinant cell, comprising the following steps: co-transfecting a pig cell with DOK7-gRNA2, DOK7-gRNA4 and NCN protein to obtain a recombinant cell. The recombinant cell is a recombinant cell with a mutated DOK7 gene. The use of any of the above kits is to prepare a recombinant cell, to prepare a muscle weakness model pig, to prepare a muscle weakness cell model, a muscle weakness tissue model or a muscle weakness organ model. The application has great application value for research and development of muscle weakness disease drugs and revealing the pathogenesis of the disease.

There remains a need for effective therapeutic agents for the treatment of TGFβ superfamily-associated disorders. [Solution] Polypeptides comprising an activin receptor type IIB (ActRIIB) ectodomain (ECD) variant are provided. In some embodiments, the polypeptides of the present disclosure comprise an ActRIIB-ECD variant fused to an Fc domain portion. The present disclosure also provides pharmaceutical compositions and methods using the polypeptides to treat diseases and conditions associated with TGF-β superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (e.g., anemia).

The invention relates to application of traditional Chinese medicine herba epimedii, especially an aqueous extract of herba epimedii and epimedin A in prevention and / or improvement of sarcopenia. Compared with a blank control group and a negative control group, the body lengths of the herba epimedii aqueous extract with the concentration of 1 mg / mL, the total flavonoids with the concentration of 0.026 mg / mL, the epimedium A with the concentration of 50 [mu] M, the epimedium B with the concentration of 200 [mu] M, the epimedium C with the concentration of 100 [mu] M, the icariin with the concentration of 200 [mu] M and the icaritin with the concentration of 100 [mu] M are increased by 21.40%, 23.09%, 26.69%, 24.91%, 29.22%, 33.15% and 28.35% respectively. The icariin administration concentration is improved, and the growth promoting effect concentration dependence is obviously enhanced. The body length of the caenorhabditis elegans is increased by 24.19% and even exceeds that of a positive control group. Epimedin A of 50 mu M can effectively increase the body length of caenorhabditis elegans, and other Epimedin A needs higher concentration; 50 [mu] M has the best effect of protecting and relieving the muscular structure. The invention provides a thought for developing medicines for improving dyskinesia and muscle volume reduction, prolonging life, improving muscle fiber atrophy, treating muscle strength decline, tonifying liver and kidney and strengthening muscles and bones, and the medicine is high in safety.

The present invention relates to a thymic tumor microenvironment antigen detection kit and its application in myasthenia gravis evaluation. The thymic tumor microenvironment antigen detection kit includes quantum dot-coupled antibody AchR, quantum dot-coupled antibody Titin, quantum dot-coupled antibody MuSK, quantum dot-coupled antibody LRP4 and quantum dot-coupled antibody RyR; quantum dot staining is performed on thymic tumor tissue sections by the kit, and different antigen staining can be performed on the same tissue section at the same time. There are differences in the expression levels of AchR, Titin, MuSK, LRP4 and RyR antigens in patients with simple thymoma, simple myasthenia gravis and thymoma combined with myasthenia gravis, and this difference can be used to distinguish the cause, course and prognosis of myasthenia gravis. The method of using quantum dots to directly carry specific antibodies eliminates the complex staining link of secondary antibodies and improves work efficiency; and observes its expression level and spatial position.

The present invention relates to a method for obtaining a functionally enhanced mitochondria and a use thereof, and specifically, to: a mitochondria isolated from cells overexpressing glutathione synthase; and a use thereof for preventing, alleviating, or treating muscle weakness-related diseases.

This invention discloses a shoulder joint exerciser, including a shoulder brace and an upper arm brace, with a hinged rod assembly between them to maintain deflection. A first rod hinged to the back of the shoulder brace is rotatably connected to the end of a second rod hinged to the back of the upper arm brace. An electric push rod is rotatably mounted on the first rod, with its output end hinged to the second rod and positioned close to the upper arm brace. The device also includes a worm gear, with worm wheels respectively mounted on the shafts connecting the first and second rods to the shoulder brace and upper arm brace, the worm gear meshing with the worm wheels. This shoulder joint exerciser has a simple structure and is easy and quick to operate. It avoids the pain or secondary injury caused by the arm falling rapidly during arm raising and lowering due to muscle weakness or poor coordination.

The present invention relates to a pharmaceutically acceptable acid addition salt comprising: (i) S-indolylcarbamate; and (ii) an organic acid, wherein the organic acid has: a pKa1 greater than or equal to 2.5; and a chemical formula of CxHy(CO2H)z, wherein x is 1 to 10, y is 2 to 20, and z is 1 or 2. The pharmaceutically acceptable acid addition salt is used to treat conditions such as cachexia, sarcopenia, neuromuscular disorders, and muscle weakness.

The apelin receptor modulator can improve the physical performance of a human patient, slow the progression of age-related weakness, and can reduce age-related muscle weakness. The present disclosure provides methods of treating muscle disorders using specific classes of apelin receptor modulators (e.g., agonists). The muscle condition may be an age-related muscle condition. Also provided is a method of maintaining and / or increasing muscle mass, muscle function, and / or muscle strength in an elderly subject by administering an apelin receptor modulator. In some embodiments, an apelin receptor modulator (e.g., an agonist) is BGE-105 or a pharmaceutically acceptable salt thereof.

The application relates to the technical field of intelligent medical auxiliary diagnosis and automatic evaluation of nerve functions, in particular to an NIHSS score automatic evaluation system for stroke patients. The system comprises a multi-modal induction and perception unit, which is used as a front-end data inlet and collects patient responses in real time to generate a video stream containing depth and color information and a synchronous audio stream; a dynamic reference calibration unit, which extracts kinematic characteristics to construct an individualized neural reference template; a neural motion frequency spectrum decomposition unit, which generates a frequency spectrum pathological characteristic vector distinguishing muscle weakness and ataxia; a contralateral mirror inhibition analysis unit, which generates compensation and driving confidence representing real neural driving intentions; a cross-modal reflection analysis unit, which generates a sensory pathway integrity index according to the difference in nerve conduction velocity; and a collaborative scoring decision engine, which maps multi-modal characteristics to a standardized NIHSS score. The application effectively eliminates the interference of age and basic physical fitness on the score, and can also provide high-precision comparison references for subsequent abnormality determination of the affected side.

The present invention relates to a pharmaceutical composition for preventing or treating diseases related to muscle weakness, which comprises alverine, 4-hydroxyalverine, a derivative thereof or a pharmaceutically acceptable salt thereof. When myoblasts are treated with alverine, 4-hydroxyalverine, a derivative thereof or a pharmaceutically acceptable salt thereof of the present invention, differentiation into myotubes is promoted. Therefore, alverine, 4-hydroxyalverine, a derivative thereof or a pharmaceutically acceptable salt thereof according to the present invention can be effectively used to promote differentiation of myoblasts and prevent or treat diseases related to muscle weakness.

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and / or cardiometabolic disease, bone damage, and / or low red blood cell levels (such as anemia).

The present invention relates to a writing device for myasthenia patients, comprising a base, an X-sliding assembly is arranged on the base, a Y-sliding assembly is slidably arranged on the X-sliding assembly; a support plate is slidably arranged on the Y-sliding assembly; a support rod is arranged on the support plate, one end of the support rod is connected to a universal movable rod, and an adapter is arranged on the universal movable rod away from one end of the support rod; a pen-holding mechanism is arranged at the lower part of the adapter. The beneficial effects are: the pen can be better supported, which is convenient for myasthenia patients to write; the myasthenia patients can better move their arms, and the arms can be better supported, and the patients can move their arms autonomously, which is conducive to autonomous writing.

This invention belongs to the pharmaceutical field and relates to the application of nikkomycin in the preparation of drugs for treating lipid storage myopathy. This invention discloses the use of nikkomycin in the treatment of lipid storage myopathy, particularly in the treatment of simple myopathic neutral lipopathy caused by PNPLA2 gene mutations. Simple myopathic neutral lipopathy is an autosomal recessive, progressive lipid storage myopathy affecting multiple systems throughout the body. Currently, there is no treatment available, and patients develop fatal symptoms such as generalized muscle weakness and cardiomyopathy in the late stages. This invention discovers that nikkomycin can significantly reverse lipid droplet deposition in fibroblasts of patients with simple myopathic neutral lipopathy, reduce inflammatory responses, improve autophagy inhibition, and increase energy production. It can serve as an effective ingredient for treating this disease and has clear application prospects in patients with untreatable simple myopathic neutral lipopathy.

The present disclosure relates to methods, uses, compositions, and kits for using testosterones or testosterone derivatives and growth hormone (GH) or GH derivatives to improve muscle mass, muscle strength, or muscle function in a subject, or to reduce fatigue, pain, or obesity. One aspect of the present disclosure relates to combination therapies of testosterones or testosterone derivatives and GH or GH derivatives for treating various disorders associated with muscle wasting or conditions associated with muscle weakness.

The present invention relates to activin receptor IIA type variants and methods of use thereof. The present invention features a polypeptide comprising an extracellular ActRIIa variant. In some embodiments, the polypeptides of the present invention comprise an extracellular ActRIIa variant fused to an Fc domain monomer or part. The invention also features the treatment of diseases and conditions involving muscle weakness and atrophy using said polypeptides, such as Duchenne muscular dystrophy, facial shoulder brachial muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; the present invention relates to pharmaceutical compositions and methods for treating a metabolic disease, such as obesity, type 1 diabetes mellitus or type 2 diabetes mellitus.

To provide an ankle supporter which centralizes a body axis, improves posture balance, distributes local stress on joints and muscles, improves movement efficiency, improves standing, walking and running ability, reduces fatigue to the body, contributes to prevention of injury, rehabilitation, health promotion and improvement of sports performance and is applicable for daily life, sports and medical care by connecting three ring-shaped supporter members to provide tension balance, covering the foot around the foot dorsum, the heel and the ankle around inner and outer malleolus from the sole, fixing and stabilizing a distal tibiofibular joint, a talocrural joint, a subtalar joint, a Chopart's joint and a Lis-Franc's joint, providing stability in all directions from front to back, from left to right and from up to down and compensating for weakened ligaments and muscle weakness.SOLUTION: In a supporter, a member (1) which wraps a periphery of a foot dorsum from a sole, a member (2) which wraps the periphery of a heel, and a member (3) which wraps the periphery of medial / lateral malleoli are connected and are attached to the periphery of a foot.SELECTED DRAWING: Figure 1

To provide a new male climacteric disorder-ameliorating composition using a safe material free from side effects, and to provide a medicine, food and drink containing the composition.SOLUTION: The male climacteric disorder-improving composition contains a treated product of an Agaricus fruit body.SELECTED DRAWING: Figure 13

The present invention belongs to the field of medical bracelets, and specifically is a wearable bracelet for medical assistance, comprising a sub-ring and a main ring, wherein a monitoring module and a control module are fixedly connected to the middle of the sub-ring, wherein the monitoring module is used to monitor the wearer's physical values, and the main ring is arranged in a ring shape, and a telescopic component is arranged on the outside of the main ring, wherein the telescopic component is used to extend outward and can be retracted after use, and the control module is used to control the telescopic component of the main ring. When the patient needs to be turned over, it is only necessary to put one hand of the patient between the patient's back and the bed, and then activate the telescopic component to push out, so that the patient's back can be pushed up by a distance of twenty centimeters on one side, so that the patient is in a semi-tilted state. At this time, the caregiver can easily push on the patient's back to let the patient turn sideways. At the same time, for patients whose muscle weakness is not very serious, the patient can put his arm behind his back and activate the telescopic component to assist the patient in the turning process.

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (such as anemia).

To provide extracellular activin receptor type IIa (ActRIIa) variants, and to provide pharmaceutical compositions containing the variants.SOLUTION: A polypeptide including an extracellular ActRIIa variant includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. A pharmaceutical composition containing the variant is used to treat diseases and conditions involving muscle weakness and muscle atrophy (for example, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia, or cancer cachexia), or metabolic diseases (for example, obesity, Type-1 diabetes, or Type-2 diabetes).SELECTED DRAWING: Figure 2A

According to the WHO, the population aged 60 and over will have doubled by 2050. Unfortunately, aging comes along with an explosion of aging-associated disorders, such as metabolic and cardiovascular diseases, bone and muscle weakening, cognitive dysfunction, that all contribute to the loss of functional capacities, leading to frailty and dependence. Now, the inventors reveal a premature aging phenotype, associating metabolic defects and muscle weakness, in a mouse model of Noonan Syndrome. Both clinical traits are linked to myeloid cells dysfunction and increased senescence, highlighting the role of SHP2 hyperactivation in the onset of aging-associated diseases. Thus the present invention relates to the use of SHP2 inhibitors for inhibiting senescence.

To provide polypeptides and pharmaceutical compositions comprising activin type IIB receptor variants.SOLUTION: The polypeptide of the present invention comprises an extracellular activin type IIB receptor (ActRIIB) mutant comprising an amino acid sequence consisting of a specific sequence, wherein the C-terminus of the ActRIIB mutant is fused to a human IgG1Fc domain monomer. The invention also features pharmaceutical compositions and methods of using the same to treat diseases and conditions involving muscle weakness and atrophy, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and / or pulmonary hypertension.SELECTED DRAWING: Figure 2

Provided are new methods for treating myasthenia gravis or other myasthenic syndromes comprising use of a therapeutically effective amount of a 5HT3-antagonist in combination with a therapeutically effective amount of a neostigmine compound, that attenuates or even abrogates the dose-limiting gastrointestinal adverse effects of neostigmine. The unique properties of the combination allow for the administration of neostigmine at markedly higher doses, e.g., about 4 times higher than recommended oral doses, and about 100 times higher than recommended parenteral doses, as compared with currently marketed products, without affecting its efficacy in treating symptoms of muscle weakness associated with myasthenia gravis or other myasthenic syndromes.